Bruker (BRKR) has reported Q1 2026 revenue of US$823.4 million with basic EPS of US$0.02, alongside trailing 12 month basic EPS of a US$0.24 loss and net income loss of US$36.4 million on revenue of US$3.5 billion. Over recent quarters, revenue has moved between US$797.4 million and US$979.6 million, while quarterly basic EPS has ranged from a US$0.41 loss to a US$0.11 profit, underscoring a mixed earnings profile. For you as an investor, this sets up an earnings season where the key question is how much of the reported revenue base can ultimately drop through to sustainable margins.

See our full analysis for Bruker.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the widely followed Bruker narratives and where the story around growth and profitability might need updating.

Trailing 12‑Month Losses Contrast With Quarterly Profit

• Across the trailing 12 months, Bruker recorded a net income loss of US$36.4 million on US$3.5b of revenue, even though the latest quarter shows a small net income of US$3.5 million.
• What stands out for a bearish view that focuses on widening losses is that trailing net losses have grown at about 22.1% per year over five years. However, recent quarters such as Q4 2025 and Q1 2026 did produce profits, which partly contrasts with the idea of a consistently worsening earnings picture.
  • Bears highlight that trailing 12 month basic EPS is a US$0.24 loss and forecasts point to continued unprofitability over the next three years, so the small Q1 2026 profit has not yet shifted the longer term pattern.
  • At the same time, quarterly basic EPS has ranged between a US$0.41 loss and a US$0.11 profit in recent periods, indicating that results have been uneven rather than a straight line of losses that fully backs the most pessimistic take.

Stay focused on how this mix of small quarterly profits and a trailing loss shapes the cautious narrative around Bruker’s earnings story before reading the 🐻 Bruker Bear Case

Revenue Near US$3.5b With Modest Growth Outlook

• Trailing 12 month revenue sits at US$3.5b, and revenue is forecast to grow at about 4.6% per year compared with a 11.4% forecast for the broader US market.
• Supporters of a more bullish framing see Bruker as a specialist supplier of scientific and diagnostic tools, and the revenue profile shows steady scale, but the 4.6% forecast growth rate and the fact that the company remained unprofitable over the trailing 12 months mean the numbers do not fully align with a simple growth story.
  • Quarterly revenue across the last six reported periods has stayed within a band of US$797.4 million to US$979.6 million, which fits a picture of a sizable installed base rather than rapid expansion.
  • The unprofitable trailing 12 month result, with a US$36.4 million net loss, gives bulls a clear hurdle, because any growth case needs to account for how that scale converts into more consistent earnings.

P/S Of 1.9x Versus Peers And DCF Fair Value Gap

• Bruker trades on a P/S of 1.9x compared with a 2.9x peer average and 3.4x for the US Life Sciences industry, and the current share price of US$43.73 sits below a cited DCF fair value of about US$49.66 and an analyst price target of US$48.36.
• For a bullish angle that leans on valuation, the combination of a share price roughly 11.9% below the DCF fair value and a lower P/S than peers appears supportive. Yet critics point out that the same dataset shows trailing 12 month losses and debt that is not well covered by operating cash flow, which keeps the valuation signal from standing on its own.
  • Investors who focus on the relative discount versus the DCF fair value and P/S peers need to weigh that against the trailing basic EPS loss of US$0.24 and the multi year pattern of losses widening at about 22.1% per year.
  • The flagged risk that debt is not well covered by operating cash flow over the last 12 months means that even if the stock looks inexpensive on revenue based multiples, balance sheet pressure remains an important part of the story.

If you are weighing whether that valuation gap offsets the profit and cash flow risks, it is worth seeing how other investors connect these dots through 📊 Read the what the Community is saying about Bruker.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Bruker's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Mixed messages on growth, margins, and valuation can pull sentiment in both directions, so consider your options while the details are fresh in mind and weigh the 2 key rewards and 1 important warning sign

See What Else Is Out There

Bruker’s trailing 12 month loss, uneven quarterly earnings, modest forecast revenue growth, and debt that is not well covered by operating cash flow highlight financial pressure.

If that mix of losses and balance sheet strain makes you cautious, it is worth moving quickly to check out stocks in the solid balance sheet and fundamentals stocks screener (44 results) that aim to pair financial resilience with fundamentally sound businesses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.